Volume 6.03 | Jan 27

Hematopoiesis News 6.03 January 27, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Genetic Engineering of Hematopoietic Stem Cells to Generate Invariant Natural Killer T Cells
Researchers report a new method to generate large numbers of invariant natural killer T (iNKT) cells in mice through T-cell receptor (TCR) gene engineering of hematopoietic stem cells (HSCs). They show that iNKT TCR-engineered HSCs could generate a clonal population of iNKT cells. [Proc Natl Acad Sci USA]
Abstract | Full Article
Learn More: StemSpan™ Myeloid Expansion Supplement
PUBLICATIONS (Ranked by impact factor of the journal)
MOZ Regulates B Cell Progenitors and, Consequently, Moz Haploinsufficiency Dramatically Retards MYC-Induced Lymphoma Development
The histone acetyltransferase MOZ (MYST3, KAT6A) is the target of recurrent chromosomal translocations fusing the MOZ gene to CBP, p300, NCOA3 or TIF2 in particularly aggressive cases of acute myeloid leukemia. Scientists report the role of wild-type MOZ in regulating B cell progenitor proliferation and hematopoietic malignancy. [Blood] Abstract

Epigenomic Analysis of the HOX Gene Loci Reveals Mechanisms that May Control Canonical Expression Patterns in AML and Normal Hematopoietic Cells
Investigators analyzed RNA sequencing data from 179 primary acute myeloid leukemia (AML) samples and normal hematopoietic cells to understand the range of expression patterns in normal versus leukemic cells. HOX expression in AML was restricted to specific genes in the HOXA or HOXB loci, and was highly correlated with recurrent cytogenetic abnormalities. [Leukemia] Abstract

Interplay of H2A Deubiquitinase 2A-DUB/Mysm1 and the p19ARF/p53 Axis in Hematopoiesis, Early T-Cell Development and Tissue Differentiation
To explore the interplay of histone H2A deubiquitinase Myb-like SWIRM and MPN domain containing1 (2A-DUB/Mysm1) with the p53 axis in the sequential differentiation of mature lymphocytes from progenitors, scientists systematically analyzed hematopoiesis and early T-cell development using Mysm1-/- and p53-/-Mysm1-/- mice. [Cell Death Differ] Full Article

Hematopoietic Stem/Progenitor Cells Express Several Functional Sex Hormone Receptors-Novel Evidence for a Potential Developmental Link between Hematopoiesis and Primordial Germ Cells
Researchers tested the expression of receptors for pituitary-derived hormones, such as follicle-stimulating hormone and luteinizing hormone, on purified murine bone marrow cells enriched for hematopoietic stem progenitor cells and tested the functionality of these receptors in ex vivo signal transduction studies and in vitro clonogenic assays. [Stem Cells Dev] Abstract

Catalase Inhibits Ionizing Radiation-Induced Apoptosis in Hematopoietic Stem and Progenitor Cells
Investigators evaluated the efficacy of catalase as a protectant against ionizing radiation (IR)-induced toxicity in hematopoietic stem and progenitor cells. The results revealed that catalase treatment markedly inhibits IR-induced apoptosis in murine hematopoietic stem cells and hematopoietic progenitor cells. [Stem Cells Dev] Abstract

Autophagy Collaborates with Ubiquitination to Downregulate Oncoprotein E2A/Pbx1 in B-Cell Acute Lymphoblastic Leukemia
With a pediatric t(1;19) B-cell acute lymphoblastic leukemia xenograft mouse model, scientists show that activation of autophagy by preventive administration of rapamycin improved the survival of leukemia animals by partial restoration of hematopoietic stem/progenitor cells, whereas treatment of the animals with rapamycin caused leukemia bone marrow cell-cycle arrest. [Blood Cancer J] Full Article


Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation with Neurological Disability in Patients with Relapsing-Remitting Multiple Sclerosis
Investigators aimed to determine the association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability and other clinical outcomes in patients with multiple sclerosis. [JAMA]
Abstract | Press Release | Editorial

Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Mixed Phenotype Acute Leukemia: Results of a Matched-Pair Analysis
Researchers retrospectively assessed the efficacy of allogeneic stem cell transplantation for mixed phenotype acute leukemia (MPAL). Eighteen patients with MPAL were identified from the transplant outcome database of KSGCT. [Eur J Haematol] Abstract

Request a Sample: ReproTeSR™
Deciphering the Transcriptional Switches of Innate Lymphoid Cell Programming: The Right Factors at the Right Time
The authors review the transcriptional circuit that specifies the development of a common innate lymphoid cell (ILC) progenitor and its subsequent programming into distinct ILC groups. [Genes Immun] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
Actinium Submits Pre-IND Meeting Request to the U.S. FDA for Its Iomab-B Drug Candidate
Actinium Pharmaceuticals, Inc. announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company’s Iomab-B drug candidate currently undergoing final preparations to start the pivotal Phase III trial in mid-2015. [Actinium Pharmaceuticals, Inc.] Press Release

Celator® Pharmaceuticals Receives FDA Fast Track Designation for CPX-351 for the Treatment of Elderly Patients with Secondary Acute Myeloid Leukemia
Celator Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for CPX-351 for the treatment of elderly patients with secondary acute myeloid leukemia. [Celator Pharmaceuticals, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Regenerative Medicine & Stem Cell (RMSC) 2015
March 19-21, 2015
Busan, South Korea

NEW World Conference on Regenerative Medicine
October 21-23, 2015
Leipzig, Germany

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Positions – Normal and Malignant Hematopoiesis (University of Copenhagen)

NEW Research Associate – Hematopoietic Stem Cells and Leukemia (City of Hope)

Director (California Institute for Regenerative Medicine)

Postdoctoral Fellow – Stem Cell/Translational Medicine (Rutgers New Jersey Medical School)

Postdoctoral Fellow – Hematopoiesis and Stem Cell Biology (Lund University)

Postdoctoral Research Scientist – Human T Cell Leukemia (Washington University School of Medicine)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

PhD Student – Experimental Leukemia Research (University Children’s Hospital Basel)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us